Category: Feature Revive

Feature Revive Features News Psychedelic Revive

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

August 5, 2020
The Cannabis Stock

TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Feature Revive News Psychedelic Revive

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

June 30, 2020
The Cannabis Stock

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Feature Revive Features News Psychedelic

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

June 12, 2020
The Cannabis Stock

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Exclusive Feature Revive Psychedelic Revive

A promising psychedelic company with a rich ip portfolio

May 22, 2020
The Cannabis Stock

Since December 2019, Revive Therapeutics| RVV (CSE) has seen a surge of more than 360% to…

Exclusive Feature Revive Features Psychedelic Revive

RVV | A penny stock that may have an Influenza / Covid-19 treatment in its hands ?

March 22, 2020
The Cannabis Stock

For several weeks, the world has been upside down due to the rapid spread of a…

Exclusive Feature Revive Features Psychedelic Revive

New coverage in cannabis pharma sector with over 1300% upside potential | Revive Therapeutics

February 8, 2020
The Cannabis Stock

Introducing New Featured Stock Pick : Revive Therapeutics Ltd. | RVV The Cannabis Stock is proud to…